2019

1. Does Glycemic Control Modulate the Impairment of NLRP3 Inflammasome Activation in Type 2 Diabetes?

   Antioxidants and Redox Signaling, Vol. 30, Núm. 2, pp. 232-240

2. The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes

   Journal of Clinical Medicine, Vol. 8, Núm. 11

3. The mitochondria-targeted antioxidant MitoQ modulates mitochondrial function and endoplasmic reticulum stress in pancreatic β cells exposed to hyperglycaemia

   Cellular Physiology and Biochemistry, Vol. 52, Núm. 2, pp. 186-197